Phase 3 trial data show that obinutuzumab significantly reduces disease activity in very active extrarenal lupus.

New analysis of Gazyva® shows the drug significantly reduces disease activity in adults with systemic lupus erythematosus.

More than three-quarters of lupus patients taking obinutuzumab (Gazvya) had a significant improvement in their symptoms after a year on the drug, researchers reported March 6 in The New England ...

March is National Kidney Month, a time to shine a light on the thousands of individuals whose lives are deeply affected by ...

Lupus is an autoimmune disease that impacts multiple systems of the body. Certain diet and lifestyle changes may improve symptoms and boost immune health. These include exercise, mindfulness and a ...

Phase III results put obinutuzumab in line for approval ...

The FDA grants Fast Track designation to nipocalimab for systemic lupus erythematosus following positive results from the phase 2b JASMINE trial.

Lupus is more common in Black people, and symptoms can be different too. Here's what to look out for and how to treat it.

Johnson & Johnson's nipocalimab has been granted U.S. Food and Drug Administration Fast Track designation as a potential treatment for adults with systemic lupus erythematosus (SLE).

Investigators assessed shear wave elastography (SWE) in detecting subclinical renal damage in patients with LN currently in clinical remission.

A woman in her 30s presented with generalised swelling and a right occipital–temporal headache. Examination showed grade 4 papilloedema, and magnetic resonance venography revealed thrombosis of the ...

For the millions of people living with lupus – a chronic autoimmune disease that can damage the kidneys, brain and other ...